Cannabidiol is a Small Molecule owned by Radius Health, and is involved in 2 clinical trials, of which 1 was completed, and 1 is planned.
Cannabidiol acts as Cannabinoid Receptor 1 and 2 agonist. The drug candidate mimic the action of endocannabinoids and augment the effect in regulating the transmission of impulses from one nerve to another. Cannabinoid receptors (CB1/2) are responsible for proliferation, motility, invasion, adhesion, and apoptosis of cancer cells. The drug candidates thereby by agonizing cannabinoid receptors elicits therapeutic activity.
The revenue for Cannabidiol is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cannabidiol NPV Report.
Cannabidiol is currently owned by Radius Health.
Cannabidiol Overview
Cannabidiol is under development for the treatment of Angelman syndrome (AS). The drug candidate is administered through oral route as a solution. It was also under development for Lennox-Gastaut syndrome and Dravet syndrome. It was also under development for chemotherapy-induced peripheral neuropathy in taxol-treated patients, pediatric schizophrenia, pontine glioma, infantile spasms, autism, unspecified indication, pediatric epilepsy (childhood absence seizures), Prader-Willi syndrome and glioblastoma.
Radius Health Overview
Radius Health, formerly NuVios Inc, is a biopharmaceutical company that develops and markets novel medicines for bone health, and endocrine diseases. The company’s marketed product includes abaloparatide injection, which is indicated for the treatment of postmenopausal women with osteoporosis. Its pipeline encompasses abaloparatide subcutaneous injection (SC) for high risk of fracture in men with osteoporosis; abaloparatide transdermal (TD) patch for postmenopausal women with osteoporosis; elacestrant (RAD1901) for estrogen-receptor (ER)-positive breast cancer; and RAD140 as an oral treatment for triple-negative, ER-positive, and ER-negative breast cancers. The company operates in Parsippany, Wayne, and Cambridge in the US. Radius Health is headquartered in Boston, Massachusetts, the US. Radius Health, formerly NuVios Inc, is a biopharmaceutical company that develops and markets novel medicines for bone health, and endocrine diseases. The company’s marketed product includes abaloparatide injection, which is indicated for the treatment of postmenopausal women with osteoporosis. Its pipeline encompasses abaloparatide subcutaneous injection (SC) for high risk of fracture in men with osteoporosis; abaloparatide transdermal (TD) patch for postmenopausal women with osteoporosis; elacestrant (RAD1901) for estrogen-receptor (ER)-positive breast cancer; and RAD140 as an oral treatment for triple-negative, ER-positive, and ER-negative breast cancers. The company operates in Parsippany, Wayne, and Cambridge in the US. Radius Health is headquartered in Boston, Massachusetts, the US.
Quick View – Cannabidiol
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies |
|
Highest Development Stage |
|